Tag:

Eli Lilly

Latest Headlines

Latest Headlines

UPDATED: FDA hands Eli Lilly a big win, OKs dulaglutide for diabetes

An embattled Eli Lilly won a major battle today, gaining the FDA's approval to market dulaglutide for Type 2 diabetes. It will be sold as Trulicity.

Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds

An FDA advisory panel wants to limit the use of testosterone drugs for safety reasons--and the proposed restrictions would shrink sales significantly. That's not good news for AbbVie, the market leader, and other drugmakers that have been riding a surge of testosterone growth.

Eli Lilly takes the lead on AstraZeneca's Alzheimer's drug in $500M deal

Longtime Alzheimer's player Eli Lilly has agreed to pay $50 million in a near-term milestone and take charge of the development work in a collaboration package worth a total of up to $500 million.

Lilly says with new data, it will seek another approval for Cyramza next year

Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.

As America's diabetes problem grows, so do prices on Lilly's Humulin

Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.

Cyramza, key to Lilly's oncology hopes, comes through in colorectal cancer

Eli Lilly's Cyramza (ramucirumab) met its primary endpoint in a study on metastatic colorectal cancer, good news for a key cog in the drugmaker's plans to capitalize on oncology.

Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice

Eli Lilly and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent challenge.

Lilly funds lawsuit over CMS Amyvid rejection

Eli Lilly's Alzheimer's imaging agent, Amyvid, can't get very far sales-wise without coverage from the Center for Medicare and Medicaid Services (CMS). And as per a September decision, that's something it doesn't have. Now, however, it's fighting back, funding litigation it couldn't file itself.

Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown

Eli Lilly took another big step toward filing its long-acting insulin peglispro for an approval, racking up some more positive HbA1c Phase III data in a head-to-head showdown with Sanofi's bestselling Lantus.

EU sets early Oct. deadline for Eli Lilly's $5.4B bid for Novartis

European Union regulators have set an Oct. 3 deadline for approving or denying Eli Lilly's $5.4 billion bid for the animal health business of Switzerland's Novartis.